GYNECARE PROSIMA* Pelvic Floor Repair System for Pelvic Organ Prolapse
This study has been completed.
Sponsor:
Ethicon, Inc.
Information provided by:
Ethicon, Inc.
ClinicalTrials.gov Identifier:
NCT00521066
First received: August 24, 2007
Last updated: November 18, 2010
Last verified: November 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to is to evaluate the success of the GYNECARE PROSIMA* system in women with symptoms for pelvic organ prolapse (POP) requiring surgical correction of POP.
(*TRADEMARK)
| Condition | Intervention |
|---|---|
|
Pelvic Organ Prolapse |
Device: GYNECARE PROSIMA* Pelvic Floor Repair System |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | A Prospective, Multi-centre Study to Evaluate the Clinical Performance of the GYNECARE PROSIMA* Pelvic Floor Repair System as a Procedure for Pelvic Organ Prolapse |
Resource links provided by NLM:
Further study details as provided by Ethicon, Inc.:
Primary Outcome Measures:
- Success based on overall POP-Q score at 12 months post-procedure. [ Time Frame: 12-months ] [ Designated as safety issue: No ]Success is determined by achievement of an overall POP-Q score of ICS Stage ≤1, without further re-intervention for POP.
Secondary Outcome Measures:
- Success based on overall POP-Q score at 24 months post-procedure. [ Time Frame: 24 months ] [ Designated as safety issue: No ]Success is determined by achievement of an overall POP-Q score of ICS Stage ≤1, without further re-intervention for POP
- Success based on treated compartment ICS POP-Q stage [ Time Frame: 12 months ] [ Designated as safety issue: No ]Success will be determined by achievement of treated compartment POP-Q score of ICS Stage ≤1, without further re-intervention for POP.
- Success based on treated compartment ICS POP-Q stage [ Time Frame: 24 months ] [ Designated as safety issue: No ]Success will be determined by achievement of treated compartment POP-Q score of ICS Stage ≤1, without further re-intervention for POP.
- Success defined as the leading edge within the hymen [ Time Frame: 12 months ] [ Designated as safety issue: No ]Success defined as the leading edge within the hymen (i.e. all POP-Q values to be less than 0, without further re-intervention for POP)
- Success defined as the leading edge within the hymen [ Time Frame: 24 months ] [ Designated as safety issue: No ]Success defined as the leading edge within the hymen (i.e. all POP-Q values to be less than 0, without further re-intervention for POP)
- Mean PFDI-20 score [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Mean PFDI-20 score [ Time Frame: 24 months ] [ Designated as safety issue: No ]
- Mean change from baseline in PFDI-20 scores [ Time Frame: 24 months ] [ Designated as safety issue: No ]
- Mean change from baseline in PFDI-20 scores [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Mean POPDI score [ Time Frame: 12 months ] [ Designated as safety issue: No ]POPDI is a sub score of PFDI-20
- Mean POPDI score [ Time Frame: 24 months ] [ Designated as safety issue: No ]POPDI is a sub score of PFDI-20
- Mean change from baseline in POPDI score [ Time Frame: 12 months ] [ Designated as safety issue: No ]POPDI is a sub scores of PFDI-20
- Mean change from baseline in POPDI score [ Time Frame: 24 months ] [ Designated as safety issue: No ]POPDI is a sub score of PFDI-20
- Mean CRADI score [ Time Frame: 12 months ] [ Designated as safety issue: No ]CRADI is a sub score of PFDI-20
- Mean CRADI score [ Time Frame: 24 months ] [ Designated as safety issue: No ]CRADI is a sub score of PFDI-20
- Mean change from baseline in CRADI score [ Time Frame: 12 months ] [ Designated as safety issue: No ]CRADI is a sub score of PFDI-20
- Mean change from baseline in CRADI score [ Time Frame: 24 months ] [ Designated as safety issue: No ]CRADI is a sub score of PFDI-20
- Mean UDI score [ Time Frame: 12 months ] [ Designated as safety issue: No ]UDI is a sub score of PFDI-20
- Mean UDI score [ Time Frame: 24 months ] [ Designated as safety issue: No ]UDI is a sub score of PFDI-20
- Mean change from baseline in UDI score [ Time Frame: 12 months ] [ Designated as safety issue: No ]UDI is a sub score of PFDI-20
- Mean change from baseline in UDI score [ Time Frame: 24 months ] [ Designated as safety issue: No ]UDI is a sub score of PFDI-20
- EuroQol (EQ-5D health state) change from baseline [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- EuroQol (EQ-5D health state) change from baseline [ Time Frame: 24 months ] [ Designated as safety issue: No ]
- Mean PFIQ-7 score [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Mean PFIQ-7 score [ Time Frame: 24 months ] [ Designated as safety issue: No ]
- Mean change from baseline in PFIQ-7 score [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Mean change from baseline in PFIQ-7 score [ Time Frame: 24 months ] [ Designated as safety issue: No ]
- Mean POPIQ score [ Time Frame: 12 months ] [ Designated as safety issue: No ]POPIQ is a sub-score of PFIQ-7
- Mean POPIQ score [ Time Frame: 24 months ] [ Designated as safety issue: No ]POPIQ is a sub-score of PFIQ-7
- Mean change from baseline in POPIQ score [ Time Frame: 12 months ] [ Designated as safety issue: No ]POPIQ is a sub-score of PFIQ-7
- Mean change from baseline in POPIQ score [ Time Frame: 24 months ] [ Designated as safety issue: No ]POPIQ is a sub-score of PFIQ-7
- Mean CRAIQ score [ Time Frame: 12 months ] [ Designated as safety issue: No ]CRAIQ is a sub-score of PFIQ-7
- Mean CRAIQ score [ Time Frame: 24 months ] [ Designated as safety issue: No ]CRAIQ is a sub-score of PFIQ-7
- Mean change from baseline in CRAIQ score [ Time Frame: 12 months ] [ Designated as safety issue: No ]CRAIQ is a sub-score of PFIQ-7
- Mean change from baseline in CRAIQ score [ Time Frame: 24 months ] [ Designated as safety issue: No ]CRAIQ is a sub-score of PFIQ-7
- Mean UIQ score [ Time Frame: 12 months ] [ Designated as safety issue: No ]UIQ is a sub-score of PFIQ-7
- Mean UIQ score [ Time Frame: 24 months ] [ Designated as safety issue: No ]UIQ is a sub-score of PFIQ-7
- Mean change from baseline in UIQ score [ Time Frame: 12 months ] [ Designated as safety issue: No ]UIQ is a sub-score of PFIQ-7
- Mean change from baseline in UIQ score [ Time Frame: 24 months ] [ Designated as safety issue: No ]UIQ is a sub-score of PFIQ-7
- Mean PISQ-12 score [ Time Frame: 12 months ] [ Designated as safety issue: No ]In subjects sexually active at baseline, assessment of sexual function
- Mean PISQ-12 score [ Time Frame: 24 months ] [ Designated as safety issue: No ]In subjects sexually active at baseline, assessment of sexual function
- Mean change from baseline in PISQ-12 score [ Time Frame: 12 months ] [ Designated as safety issue: No ]In subjects sexually active at baseline, assessment of sexual function
- Mean change from baseline in PISQ-12 score [ Time Frame: 24 months ] [ Designated as safety issue: No ]In subjects sexually active at baseline, assessment of sexual function
- Incidence of new onset dyspareunia, resolution or continuance of pre-existing dyspareunia [ Time Frame: ongoing ] [ Designated as safety issue: Yes ]
- Length of procedure [ Time Frame: perioperative ] [ Designated as safety issue: Yes ]From time to first incision to time of last suture used to secure VSD
- Pain score measured using Visual Analog Scale (VAS). [ Time Frame: 24 hours post surgery and at the 3-4 week visit ] [ Designated as safety issue: Yes ]
- Discomfort of balloon removal, measured using VAS at time of removal. [ Time Frame: 24 hrs post-surgical ] [ Designated as safety issue: Yes ]
- Subject perception of VSD: Awareness [ Time Frame: 3-4 week visit ] [ Designated as safety issue: No ]Measured by visual analogue scale
- Subject perception of VSD: Discomfort [ Time Frame: 3-4 week visit ] [ Designated as safety issue: No ]Measured by visual analogue scale
- Subject perception of VSD: Acceptability of discharge [ Time Frame: 3-4 week visit ] [ Designated as safety issue: No ]Measured by visual analogue scale
- Subject global impression [ Time Frame: 12 month visit ] [ Designated as safety issue: No ]assessed on a 5 point Likert scale
- Subject global impression [ Time Frame: 24 month visit ] [ Designated as safety issue: No ]assessed on a 5 point Likert scale
| Enrollment: | 150 |
| Study Start Date: | June 2007 |
| Study Completion Date: | June 2010 |
| Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
Prosima Pelvic Floor Repair System
|
Device: GYNECARE PROSIMA* Pelvic Floor Repair System
procedure for pelvic organ prolapse
Other Name: mesh pelvic floor repari
|
Detailed Description:
The GYNECARE PROSIMA* system provides a simplified mesh repair, avoiding the need for dissection outside the pelvic cavity.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Women over 18 with symptomatic pelvic organ prolapse of ICS POP-Q Stage II or III, suitable for surgical repair
Criteria
Inclusion Criteria:
- Candidates with symptomatic pelvic organ prolapse of ICS POP-Q Stage II or III, suitable for surgical repair. Vaginal hysterectomy, perineal repair and/or mid urethral sling procedures for incontinence may be performed concurrently.
- Age ≥ 18 years.
- Agrees to participate in the study, including completion of all study-related procedures, evaluations and questionnaires, and documents this agreement by signing the Ethics Committee / IRB approved informed consent.
Exclusion Criteria:
- Additional surgical intervention concurrent to the PROSIMA procedure (e.g. sacrocolpopexy, paravaginal repair, tubal sterilisation).
- Previous repair of pelvic organ prolapse involving insertion of mesh.
- Previous hysterectomy within 6 months of scheduled surgery.
- Experimental drug or experimental medical device within 3 months prior to the planned procedure.
- Active genital, urinary or systemic infection at the time of the surgical procedure. Surgery may be delayed in such subjects until the infection is cleared.
- Coagulation disorder or on therapeutic anticoagulant therapy at the time of surgery.
- History of chemotherapy or pelvic radiation therapy.
- Systemic disease known to affect bladder or bowel function (e.g. Parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury or trauma).
- Current evaluation or treatment for chronic pelvic pain (e.g. interstitial cystitis, endometriosis, coccydynia, vulvodynia).
- Nursing or pregnant or intends future pregnancy.
- In the investigator's opinion, any medical condition or psychiatric illness that could potentially be life threatening or affect their ability to complete the study visits according to this protocol.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00521066
Locations
| United States, Florida | |
| Specialists in Urology | |
| Naples, Florida, United States, 34102 | |
| United States, Michigan | |
| Female Pelvic Medicine and Urogynecology Institute of Michigan | |
| Dearborn, Michigan, United States, 48124 | |
| Female Pelvic Medicine & Urogynecology | |
| Grand Rapids, Michigan, United States, 49506 | |
| United States, Pennsylvania | |
| The Institute for Female Pelvic Medicine & Reconstructive Surgery | |
| Allentown, Pennsylvania, United States, 18104 | |
| Magee Women's Hospital of the Universtiy of Pittsburgh | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Australia | |
| Royal Women's Hospital | |
| Melbourne, Australia, 3053 | |
| Germany | |
| Bereich Urogynakologie | |
| Halle, Germany, 06097 | |
| Universitatsklinik Tubingen | |
| Tubingen, Germany, 72076 | |
| United Kingdom | |
| Addenbrookes Hospital | |
| Cambridge, United Kingdom, CB2 0QQ | |
| North Hampshire Hospital | |
| Hampshire, United Kingdom, RG24 9NA | |
| St. Mary's Hospital | |
| Manchester, United Kingdom, M13 0JH | |
Sponsors and Collaborators
Ethicon, Inc.
Investigators
| Study Director: | David Robinson, M.D. | Ethicon, Inc. |
More Information
No publications provided
| Responsible Party: | David Robinson, MD / Medical Director, Ethicon Inc |
| ClinicalTrials.gov Identifier: | NCT00521066 History of Changes |
| Other Study ID Numbers: | 300-06-005 |
| Study First Received: | August 24, 2007 |
| Last Updated: | November 18, 2010 |
| Health Authority: | United States: Institutional Review Board United Kingdom: Research Ethics Committee Germany: Ethics Commission Australia: Human Research Ethics Committee |
Additional relevant MeSH terms:
|
Prolapse Pelvic Organ Prolapse Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on May 22, 2013